Immune modulation by tryptophan metabolism: Relevance for autoimmune and tumor diseases;Immunmodulation durch Tryptophanstoffwechsel: Klinische Relevanz für Autoimmun- und Tumorerkrankungen

Deutsche Medizinische Wochenschrift

Volumn 138, Issue 28-29, 2013, Pages 1478-1482

  Platten, M ^a   Wick, W ^a   Opitz, C ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

glioblastome; multiple sclerosis; nutrition; tryptophan

Indexed keywords

AUTOIMMUNE DISEASE; IMMUNOMODULATION; NEOPLASM; REVIEW; TRYPTOPHAN METABOLISM;

ANIMALS; AUTOIMMUNE DISEASES; BRAIN; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNE TOLERANCE; IMMUNOMODULATION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; KYNURENINE; MICE; NEOPLASMS; SEROTONIN; TREATMENT OUTCOME; TRYPTOPHAN;

EID: 84879910381     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0033-1343222     Document Type: Review

References (14)

1. Balachandran V. P., Cavnar M. J., Zeng S. et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med: 2011; 17 1094 1100
2. Esser C., Rannug A., Stockinger B. The aryl hydrocarbon receptor in immunity. Trends Immunol: 2009; 30 447 454
3. Fallarino F., Grohmann U., Puccetti P. Indoleamine 2,3-dioxygenase: From catalyst to signaling function. Eur J Immunol: 2012; 42 1932 1937
4. NICE Munn D. H. Blocking IDO activity to enhance anti-tumor immunity. Front Biosci (Elite Ed): 2012; 4 734 745
5. Munn D. H., Zhou M., Attwood J. T. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science: 1998; 281 1191 1193
6. Opitz C. A., Litzenburger U. M., Sahm F. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature: 2011; 478 197 203
7. Opitz C. A., Wick W., Steinman L. et al. Tryptophan degradation in autoimmune diseases. Cell Mol Life Sci: 2007; 64 2542 2563
8. Peng W., Robertson L., Gallinetti J. et al. Surgical stress resistance induced by single amino acid deprivation requires Gcn2 in mice. Sci Transl Med: 2012; 4 118ra111
9. Pilotte L., Larrieu P., Stroobant V. et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A: 2012; 109 2497 2502
10. Platten M., Ho P. P., Youssef S. et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science: 2005; 310 850 855
11. Platten M., Litzenburger U., Wick W. The aryl hydrocarbon receptor in tumor immunity. Oncoimmunology: 2012; 1 396 397
12. Prendergast G. C. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene: 2008; 27 3889 3900
13. Schwarcz R., Bruno J. P., Muchowski P. J. et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci: 2012; 13 465 477
14. Zwilling D., Huang S. Y. et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell: 2011; 145 863 874